Evidence map›Paper›PMID 35151370›Full record

ArticleActa neuropathologica communications2022

A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.

Gaël Nicolas, Myriam Sévigny, François Lecoquierre, Florent Marguet, Andréanne Deschênes, Maria Carment Del Pelaez, Sébastien Feuillette, Anaïs Audebrand, Magalie Lecourtois, Stéphane Rousseau and 22 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Journal of Cancer · 2024
    Article
  4. Article
  5. Article
  6. Functions and mechanisms of the GPCR adaptor protein Norbin.Biochemical Society transactions · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 8 institutions in 6 countries.

Gaël Nicolas *Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.ORCID 0000-0001-9391-7800
Myriam Sévigny *Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
François LecoquierreInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Florent MarguetInserm U1245 and CHU Rouen, Department of Pathology, Normandie University, UNIROUEN, F-76000, Rouen, France.
Andréanne DeschênesDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
Maria Carment Del PelaezDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
Sébastien FeuilletteInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Anaïs AudebrandDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
Magalie LecourtoisInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Stéphane RousseauInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Anne-Claire RichardInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Kévin CassinariInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Vincent DeramecourtLille Neuroscience and Cognition (Inserm UMRS1172) Alzheimer and Tauopathies, Laboratory of Excellence Distalz (Development of Innovative Strategies for a Transdisciplinary Approach to ALZheimer's Disease), University of Lille, CHU Lille, Lille, France.
Charles DuyckaertsINSERM, CNRS U1127, Institut du Cerveau, Sorbonne Université, ICM, Paris, France.
Anne BolandCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Jean-François DeleuzeCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Vincent MeyerCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Jordi Clarimon EchavarriaMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ellen GelpiNeurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS, Barcelona, Spain.
Haruhiko AkiyamaDementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
Masato HasegawaDementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
Ito KawakamiDementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
Tsz H WongDepartment of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
Jeroen G J Van RooijDepartment of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
John C Van SwietenDepartment of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
Dominique CampionInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
Paul A DutchakDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
David WallonUNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology and CNR-MAJ, Normandie University, F-76000, Rouen, France.
Flavie Lavoie-CardinalDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
Annie LaquerrièreInserm U1245 and CHU Rouen, Department of Pathology, Normandie University, UNIROUEN, F-76000, Rouen, France.
Anne Rovelet-LecruxInserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France. anne.roveletlecrux@univ-rouen.fr.ORCID 0000-0003-4454-3659
Chantelle F SephtonDepartment of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6. chantelle.sephton.1@ulaval.ca.ORCID 0000-0002-9839-0611
Inserm · FRUniversité Laval · CACommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRErasmus MC · NLTokyo Metropolitan Institute of Medical Science · JPCentre National de la Recherche Scientifique · FRConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frontotemporal dementia (FTD) is a heterogeneous clinical disorder characterized by progressive abnormalities in behavior, executive functions, personality, language and/or motricity. A neuropathological subtype of FTD, frontotemporal lobar degeneration (FTLD)-FET, is characterized by protein aggregates consisting of the RNA-binding protein fused in sarcoma (FUS). The cause of FTLD-FET is not well understood and there is a lack of genetic evidence to aid in the investigation of mechanisms of the disease. The goal of this study was to identify genetic variants contributing to FTLD-FET and to investigate their effects on FUS pathology. We performed whole-exome sequencing on a 50-year-old FTLD patient with ubiquitin and FUS-positive neuronal inclusions and unaffected parents, and identified a de novo postzygotic nonsense variant in the NCDN gene encoding Neurochondrin (NCDN), NM_014284.3:c.1206G > A, p.(Trp402*). The variant was associated with a ~ 31% reduction in full-length protein levels in the patient's brain, suggesting that this mutation leads to NCDN haploinsufficiency. We examined the effects of NCDN haploinsufficiency on FUS and found that depleting primary cortical neurons of NCDN causes a reduction in the total number of FUS-positive cytoplasmic granules. Moreover, we found that these granules were significantly larger and more highly enriched with FUS. We then examined the effects of a loss of FUS function on NCDN in neurons and found that depleting cells of FUS leads to a decrease in NCDN protein and mRNA levels. Our study identifies the NCDN protein as a likely contributor of FTLD-FET pathophysiology. Moreover, we provide evidence for a negative feedback loop of toxicity between NCDN and FUS, where loss of NCDN alters FUS cytoplasmic dynamics, which in turn has an impact on NCDN expression.

Indexed as

BrainCodon, NonsenseFemaleFrontotemporal DementiaHaploinsufficiencyHumansMiddle AgedNerve Tissue ProteinsNeuronsRNA-Binding Protein FUSCodon, NonsenseFUS protein, humanNCDN protein, humanNerve Tissue ProteinsRNA-Binding Protein FUSCytoplasmic granulesDe novo mutationFrontotemporal dementia (FTD)FTLD-FETFUS (fused in sarcoma)Genetic variantmGluR1/5NCDN (neurochondrin)NeurodegenerationNorbin

Identifiers

PMID35151370
PMCPMC8841087
OpenAlexW4211137489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.